Quadruplet daratumumab in combination with bortezomib, lenalidomide, and dexamethasone as front-line regimen improved clinical outcomes in high-risk myeloma patients in China: a multi-centered prospec
a day ago
- #real-world study
- #multiple myeloma
- #quadruplet regimen
- Quadruplet regimen (daratumumab, bortezomib, lenalidomide, dexamethasone) improves clinical outcomes in high-risk myeloma patients in China.
- Multi-centered, prospective real-world study conducted with ethics approval from Peking Union Medical College Hospital.
- Study highlights efficacy of front-line quadruplet therapy for high-risk multiple myeloma patients.
- No competing interests declared by the authors.
- References include recent studies on triplet therapy, daratumumab combinations, and updated multiple myeloma management guidelines.